Reuters logo
BRIEF-Axovant Sciences Q3 loss per share $0.48
February 14, 2017 / 9:25 PM / 9 months ago

BRIEF-Axovant Sciences Q3 loss per share $0.48

Feb 15 (Reuters) - Axovant Sciences Ltd :

* Axovant Sciences announces dementia pipeline updates and reports financial results for the third fiscal quarter and nine months ended december 31, 2016

* Q3 loss per share $0.48

* Q3 earnings per share view $-0.46 -- Thomson Reuters I/B/E/S

* Says clinical programs are on-track to produce results from multiple late-stage clinical studies in 2017

* Axovant Sciences Ltd- expects full study of nelotanserin in lewy body dementia patients to complete in mid-2017

* Axovant Sciences Ltd- expects top-line results from phase 3 mindset study in Q3 of 2017

* Plans to expand patient recruitment to confirm treatment benefits observed in interim results from this ongoing study

* Axovant Sciences - expects top-line results from phase 2b study of intepirdine in patients with dementia with lewy bodies headway-dlb study, in Q4 2017 Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below